Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Riboflavin Metabolism Variation among Clinical Isolates of Streptococcus pneumoniae Results in Differential Activation of Mucosal-associated Invariant T Cells.

Hartmann N, McMurtrey C, Sorensen ML, Huber ME, Kurapova R, Coleman FT, Mizgerd JP, Hildebrand W, Kronenberg M, Lewinsohn DM, Harriff MJ.

Am J Respir Cell Mol Biol. 2018 Jun;58(6):767-776. doi: 10.1165/rcmb.2017-0290OC.

2.

Regionally compartmentalized resident memory T cells mediate naturally acquired protection against pneumococcal pneumonia.

Smith NM, Wasserman GA, Coleman FT, Hilliard KL, Yamamoto K, Lipsitz E, Malley R, Dooms H, Jones MR, Quinton LJ, Mizgerd JP.

Mucosal Immunol. 2018 Jan;11(1):220-235. doi: 10.1038/mi.2017.43. Epub 2017 May 17.

3.

Capacity of Pneumococci to Activate Macrophage Nuclear Factor κB: Influence on Necroptosis and Pneumonia Severity.

Coleman FT, Blahna MT, Kamata H, Yamamoto K, Zabinski MC, Kramnik I, Wilson AA, Kotton DN, Quinton LJ, Jones MR, Pelton SI, Mizgerd JP.

J Infect Dis. 2017 Aug 15;216(4):425-435. doi: 10.1093/infdis/jix159.

4.

Myeloid ZFP36L1 does not regulate inflammation or host defense in mouse models of acute bacterial infection.

Hyatt LD, Wasserman GA, Rah YJ, Matsuura KY, Coleman FT, Hilliard KL, Pepper-Cunningham ZA, Ieong M, Stumpo DJ, Blackshear PJ, Quinton LJ, Mizgerd JP, Jones MR.

PLoS One. 2014 Oct 9;9(10):e109072. doi: 10.1371/journal.pone.0109072. eCollection 2014.

6.

Human monoclonal antibodies to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strains.

Pier GB, Boyer D, Preston M, Coleman FT, Llosa N, Mueschenborn-Koglin S, Theilacker C, Goldenberg H, Uchin J, Priebe GP, Grout M, Posner M, Cavacini L.

J Immunol. 2004 Nov 1;173(9):5671-8. Erratum in: J Immunol. 2007 Jun 1;178(11):7485.

7.

The galU Gene of Pseudomonas aeruginosa is required for corneal infection and efficient systemic spread following pneumonia but not for infection confined to the lung.

Priebe GP, Dean CR, Zaidi T, Meluleni GJ, Coleman FT, Coutinho YS, Noto MJ, Urban TA, Pier GB, Goldberg JB.

Infect Immun. 2004 Jul;72(7):4224-32.

8.

Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine.

Theilacker C, Coleman FT, Mueschenborn S, Llosa N, Grout M, Pier GB.

Infect Immun. 2003 Jul;71(7):3875-84.

9.
10.

Hypersusceptibility of cystic fibrosis mice to chronic Pseudomonas aeruginosa oropharyngeal colonization and lung infection.

Coleman FT, Mueschenborn S, Meluleni G, Ray C, Carey VJ, Vargas SO, Cannon CL, Ausubel FM, Pier GB.

Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1949-54. Epub 2003 Feb 10.

11.

Construction and characterization of a live, attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccine.

Priebe GP, Brinig MM, Hatano K, Grout M, Coleman FT, Pier GB, Goldberg JB.

Infect Immun. 2002 Mar;70(3):1507-17.

12.

Transgenic cystic fibrosis mice exhibit reduced early clearance of Pseudomonas aeruginosa from the respiratory tract.

Schroeder TH, Reiniger N, Meluleni G, Grout M, Coleman FT, Pier GB.

J Immunol. 2001 Jun 15;166(12):7410-8.

14.

NLRB unit determinations expanding?

Coleman FT, Sperling L.

Hosp Prog. 1976 Aug;57(8):43-6,66. No abstract available.

PMID:
939531

Supplemental Content

Loading ...
Support Center